These previous observations, as well as the presented case, might be explained by the fact that some lesions require a longer time to internalize PSMA-targeted tracer, and, in addition, the tumor-to-background ratio increases over time due to progressive elimination of the radiopharmaceutical. This evidence concerns the gene FOLH1 and neoplasm.